Delivery Order SPE2DB24D2105-SPE2DB25FAQHD
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,046.81 to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Olopatadine HCL 0.1% eye drops in 5ml quantities. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 26, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its Corporate Office location in Conshohocken, PA....
- The Defense Logistics Agency awarded a $1,434.04 delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Olopatadine HCL 0.1% eye drops in 5ml quantities. This firm fixed-price contract, with an ultimate completion date of August 25, 2025, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting open competition among qualified pharmaceutical vendors....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Olopatadine HCL 0.1% eye drops in 5mL quantities, valued at $2,587.17. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award to the vendor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 27, 2025. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,708.86 to AmerisourceBergen Drug Corp for the supply of Olopatadine HCL 0.1% eye drops in 5ml units. This firm fixed price delivery order, awarded on August 8, 2025, is set to be completed by August 11, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The contract represents a non-set-aside competitive award, demonstrating AmerisourceBergen's capability to fulfill...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Olopatadine HCL 0.1% eye drops (5 mL units) with a ceiling value of $1,148.94. This firm fixed-price delivery order is not set-aside and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 through December 2026. The pharmaceutical products will be...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Olopatadine HCL 0.1% Eye Drops (5ML) with a ceiling value of $2,789.33. The contract, which is a firm fixed-price delivery order, was awarded on May 9, 2025, with an ultimate completion date of May 12, 2025. This award does not include a set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The $1,424.20 delivery order is for the supply of Olopatadine HCL 0.1% eye drops in 5ml containers. The contract has a firm fixed price pricing type and an ultimate completion date of October 17, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop...
- The Defense Logistics Agency awarded a $3,181.65 delivery order to AmerisourceBergen Drug Corp for Olopatadine HCL 0.1% eye drops (5ml) on June 16, 2025, with an ultimate completion date of June 17, 2025. This firm fixed-price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,380.55 to AmerisourceBergen Drug Corp for the supply of Olopatadine HCL 0.1% eye drops (5 mL units). This firm fixed price, competitively awarded contract was executed on July 18, 2025, with an ultimate completion date of July 21, 2025. The contract represents a non-set-aside award and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,757.44 to AmerisourceBergen Drug Corp for the supply of Olopatadine HCL 0.1% eye drops (5 mL) under a firm fixed-price contract. The award, issued on May 30, 2025, with an ultimate completion date of June 2, 2025, represents a non-competitive delivery order with no set-aside designation. Performance of this order will be executed from the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery...
- SPE2DB24D2105Indefinite Delivery Contract
- SPE2DB24D2105-SPE2DB25FAQHDDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Olopatadine HCL 0.1% eye drops (5ml) with a ceiling value of $3,491.87. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is due for completion by September 26, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This award represents a routine pharmaceutical procurement fulfilling DLA's medical supply needs. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen regularly fulfills pharmaceutical and medical supply requirements for military and veteran healthcare systems through this comprehensive contract vehicle. The company's extensive portfolio of federal awards demonstrates its established capability to supply a wide range of brand-name and generic medications, vaccines, and medical supplies to support defense healthcare programs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 9/25/25 |